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ABSTRACT: Skin cancer is one of the most occurring cancers in the world and its 
occurrence is rising. Many factors contribute to the development of skin cancers 
such as UV light exposure, chronic inflammation, and genetic susceptibility. 
Cancers such as basal cell carcinomas and squamous cell carcinomas arise from 
cells within the epidermis. TP53 and TP63, members of the p53 protein family, play 
a major role in skin tumorigenesis and progression. While p53 is the most mutated 
gene in human cancers, p63 is seldom mutated in cancers. The functions of p53, 
“guardian of the genome”, have been well documented and studied. Nonetheless, 
many studies show that p63 is overexpressed in tumors. Other studies show that 
p63 is lost during tumorigenesis and cancer progression. Consequently, whether 
the p63 gene is a tumor suppressing gene or an oncogene remains a matter of the 
p63 protein’s isoforms present in these tumors and their interactions with p53 and 
MDM2. This challenge has two facets. First, the multiple spliced isoforms of p53 
and p63 which have different functions in skin development as well as skin cancers. 
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Second, the Mouse Double Minute 2 (MDM2) protein, a negative regulator of p53, 
which has been shown to have different proteomic affinities by which it binds these 
different p53 and p63 isoforms. The findings of this project are geared toward 
characterizing and semi-quantifying the histopathological expression of p63, p53 
and MDM2 in cutaneous basal cell carcinomas as well as squamous cell 
carcinomas, while addressing the aggregation propensities between these proteins. 
The project also aims to summarize the forensic use of p53 and p63 as potential 
biomarkers for the estimation of age in antemortem and postmortem wounds and 
lesions. We have used advanced softwares such as ImageJ from the NIH and 
QuPath to extract important data to better characterize the layer-by-layer 
expression of p53, p63, and MDM2 in specific areas such as the epidermis, the 
dermal layer, stroma, and tumor nests. We used multiple skin tumor biopsies and 
excisions from three different skin cancer patients. The molecular simulations using 
the PASTA 2.0, AGGRESCAN, and FELLS webservers is to compare and contrast 
the aggregation propensities of p53 and p63 and what locations of their protein 
sequences are hot spots for aggregation. Results showed that p63 has the most 
stain intensity and was strictly nuclear in all three cases (p-value of 0.0007). The 
consistent expression of p63 in all three cases indicates the important role of p63 in 
the tumorigenesis of skin epithelial cells and dysplasia. MDM2 has been shown to 
have a strong stain intensity both nuclear and cytoplasmic in all three cases but was 
of no significance in differentiating our cases (p-value of 0.718). p53 was partially 
absent in all three cases and had a weak stain intensity when present (p-value of 
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0.086). Data from the FELLS, PASTA 2.0, and AGGRESCAN showed that p53 has 
the highest number of residues susceptible to aggregation at 27.48% (108 
residues), whereas p63 and MDM2 have aggregation percentages of 7.94% (54 
residues) and 3.67% (18 residues) respectively. Clinically, studies show that p63, 
particularly the ∆Np63 isoform, has an essential role in epithelial wound repair. 
Forensically, studies show that p53’s expression increased in wounds with an 
interval of post-infliction of three to 77 days. This makes p53 a potential candidate 
for wound age estimation in ante-mortem wounds with longer survival time after the 
injury. Research also shows that these later conclusions cannot be applied to 
postmortem wounds and that further research is needed to evaluate the potential 
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Project Importance and Field Contributions  
Over five million people are diagnosed with basal cell and squamous cell 
carcinomas every year. The findings of this project are to expand our understanding 
of the specific proteins’ tissue expression, aggregation, and the effects of these 
proteins on cutaneous tumorigenesis, cancer progression, and downstream forensic 
pathology uses. The importance of this project lies in that it allows for the qualitative 
and semi-quantitative characterization of tumor tissue expression of p63, p53, and 
MDM2 in two histologically distinct cancers and to also use skin cancer biopsies as 
templates for future forensic skin wound age determination studies. These proteins 
are extensively investigated due to their important functional interactions necessary 
for tumorigenesis, apoptosis, and potential treatment for many human cancers. The 
presence of multiple isoforms of both p63 and p53 is another major confounding 
area in the study of these proteins, which is yet to be investigated by further 
research. Results can then be compared to and possibly complement previous 
findings. Both faculty and future UCO students interested in the field of histology, 
digital image processing, and software-assisted proteomic analyses can use the 
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Rationale and Hypothesis  
We hypothesize that since basal cell carcinoma and squamous cell 
carcinoma are two distinct cancers histologically, then the IHC quantification of p63, 
p53, and MDM2’s protein expression in the skin tissues will be different at the three 
major skin layers: the epidermis, the dermis, and the subcutaneous layers. The 
basis behind the hypothesis is that these proteins interact differently with each other 
depending on the presence or absence of mutant p53, TAp63, and ∆Np63 isoforms. 
These protein-to-protein interactions and aggregations remain complex to 
understand and have significant outcomes on tumorigenesis, progression, and 
prognosis of many cancers.  
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CHAPTER ONE: THESIS INTRODUCTION  
 Basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) are the 
most occurring non-melanoma cancers and their incidence continue to rise (Geller 
and Annas 2003). The histological features of both BCC and SCC are well 
documented in the field of pathology and often times proper diagnosis is easily 
achieved based on clinical information (Ryu et al., 2018). However, Studies such as 
the one by Ryu et al., (2018) showed that SCCs have a higher chance to be 
clinically misdiagnosed as BCCs than Vice versa. p63 and p73 are homologous 
proteins of the tumor protein p53 and collectively these transcription proteins make 
up the p53 protein family (Yang et al., 1999). While both p63 and p73 can bind the 
p53 DNA promoters and induce processes such as apoptosis and cellular cycle 
arrest, both proteins have distinct and different functions than those of p53 (Yang et 
al., 2000). Unlike p53, p63 and p73 have distinct tissue specific patterns of 
expression mainly in ectodermally-derived tissues such the skin and the nervous 
system, respectively (Pozniak et al., 2000). During human development, p63 
induces the formation of epidermal tissue and the associated structures such as 
teeth, hair, and glands. In mature skin, p63 maintains the proliferation of epidermal 
and dermal stem cells which ensures the homeostasis and regeneration. This also 
ensures the specific commitment of keratinocytes towards terminal differentiation 
and stratification (Laurikkala et al., 2006) and (Su 2009). On the other hand, p73 is 
mainly associated with the development and the homeostasis of the nervous 
system (Pozniak et al., 2002) and (Truong 2006).   
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 Although p53 has been known as the “guardian of the genome” for many 
years with its direct roles in tumor suppression and apoptosis, the discovery and 
study of its cousin proteins p63 and p53 yielded a great amount of research. Many 
studies focus on the roles of p63 and p53 in skin development and cancers alike 
(Ryu et., 2018). p53 and its related protein p63 and p73 make up the p53 tumor 
protein family. While p53 is the commonly mutated gene in many human cancers, 
p63 is seldom mutated or deleted. However, many cancers show an over-
expression of p63 (Inoune and Fry 2014). Previous studies have shown that the 
loss of p63 is associated with tumorigenesis and cancer progression. As a result, 
whether p63 acts a tumor suppressor or as an oncogene has been argued. The 
reason for this, is that variably expressed p63 isoforms (via alternative splicing) 
appear to have different functions that are both like and different from p53 (Inoune 
and Fry 2014). There are strong structural similarities between p53 and p63 which 
allow p63 to bind to conventional p53 components (Stindt et al,. 2014). However, 
p63 has a very distinct function which plays a pivotal role in skin and limb 
development (Lustig 2012).  For example, p63 dependent processes range from 
epidermal development of linages, to epidermis differentiation, and basement 
membrane formation (Stindt et al., 2014). Nearly all human tumors possess 
inactivating mutations in tumor suppressing proteins such as p53 which is crucial for 
cell cycle checkpoints and apoptosis. The p63 protein is an essential protein for skin 
development, maintenance, and has six main isoforms (Rangel et al., 2014). 
The TAp63 isoforms (α, β, γ) can bind to DNA via p53 response elements 
(REs) and induce gene activation for cell cycle arrest and apoptosis (Rangel et al., 
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2014). It can also inhibit terminal cell differentiation (Rangel et al., 2014). The 
ΔNp63 isoforms (α, β, γ) can also bind to DNA via p53 REs while exerting a 
dominant effect on p53, p73, and p63. This happens via competition for DNA 
binding sites or by protein-protein interactions (Rangel et al., 2014). Many cancers 
express mutant p53 proteins without the wild type tumor suppressing activity via a 
single missense mutation resulting in a single amino acid change (Stindt et al., 
2014). Cancerous cells with wild-type p53 are expected to be more susceptible to 
cytotoxicity than those with mutant p53. However, wild-type p53 has been shown to 
enhance the pro-survival functions and increase survival advantages of cells. 
Mutant p53 can interact via aggregation with other proteins such as p63, p73, 
MDM2, and even wild type p53 (Inoune and Fry 2014). The MDM2 protein is a 
negative regulator of p53 which is responsible for p53 degradation and may have a 
binding affinity to p63 (Rangel et al., 2014). Some of these proteins can acquire 







From Cancer to Forensics: The Immunohistochemical Characterization of TP63, TP53, and MDM2 Proteins 




Geller, Alan C, & Annas, George D. (2003). Epidemiology of melanoma and 
  nonmelanoma skin cancer. Seminars in Oncology Nursing, 19(1), 2–11. 
 https://doi.org/10.1053/sonu.2003.50000 
Inoue, K., & Fry, E. A. (2014). Alterations of p63 and p73 in human cancers. In  
Mutant p53 and MDM2 in Cancer (pp. 17-40). Springer Netherlands. 
Laurikkala J. p63 regulates multiple signaling pathways required for ectodermal 
organogenesis and differentiation. Development. 2006;133(8):1553. 
Lustig, D. (2012). Molecular Mechanisms of p63-Derived Ectodermal Dysplasia. A  
thesis submitted in conformity with the requirements for the degree of Master 
of Science Institute of Medical Science University of Toronto.  
Pozniak CD. An anti-apoptotic role for the p53 family member, p73, during  
developmental neuron death. Science. 2000;289(5477):304. 
Pozniak CD. p73 is required for survival and maintenance of CNS neurons. The  
Journal of neuroscience. 2002;22(22):9800 
Rangel, Luciana P, Costa, Danielly CF, Vieira, Tuane CRG, & Silva, Jerson L. 
 (2014).The aggregation of mutant p53 produces prion-like properties in  
cancer. Prion, 8(1), 75–84.https://doi.org/10.4161/pri.27776  
Ryu, T. H., Kye, H., Choi, J. E., Ahn, H. H., Kye, Y. C., & Seo, S. H. (2018).  
Features Causing Confusion between Basal Cell Carcinoma and Squamous 
 Cell Carcinoma in Clinical Diagnosis. Annals of dermatology, 30(1), 64–70.  
https://doi.org/10.5021/ad.2018.30.1.64 
Stindt M H, Muller P A J, Ludwig R L, Kehrloesser S, Dötsch V, & K H Vousden.  
(2014). Functional interplay between MDM2, p63/p73 and mutant p53.  
Oncogene, Oncogene, 2014. 
Su X. TAp63 prevents premature aging by promoting adult stem cell maintenance.  
Cell stem cell. 2009;5(1):64. 
From Cancer to Forensics: The Immunohistochemical Characterization of TP63, TP53, and MDM2 Proteins 
Expression in Skin Basal Cell and Squamous Cell Carcinomas. 
5 
 
Yang A. p63 is essential for regenerative proliferation in limb, craniofacial and        
epithelial development. Nature. 1999;398(6729):714. 
Yang A. p73-deficient mice have neurological, pheromonal and inflammatory   






















From Cancer to Forensics: The Immunohistochemical Characterization of TP63, TP53, and MDM2 Proteins 
Expression in Skin Basal Cell and Squamous Cell Carcinomas. 
6 
 
CHAPTER TWO: THE p53, p63, p73 TRIO: AN EVOLUTIONARY 
FAMILLY AFFAIR OF HOMOLGY AND DIVERSE FUNCTIONLATY.  
1. The p53, p63, MDM2 Protein Trio 
1.1. Tumor Protein p53 
The p53 protein is an important transcription factor involved in many physio-
cellular pathways, especially that of programmed cell death (known as apoptosis), 
DNA repair, and cell cycle control (Oren 2003). This homo-tetrameric protein has 
three main functional and structural domains. These include the transactivation 
domain (TA) at the N-terminal which activates other genes, the DNA binding domain 
(DBD) which binds the promoter region of other p53 induced genes, and the 
oligomerization domain at the C-terminal which is responsible for the 
phosphorylation and acetylation of the p53 gene (Romer et al., 2006). Recent 
studies have proposed that the formation of mutant p53 is strongly associated with 
some pathological effects including gain-of-function (GoF), loss-of-function (LoF), 
and domain-negative (DN) (Costa et al., 2016). These later proteomic effects play a 
pivotal role in tumorigenesis and cancer progression. p53 is lost in nearly half of all 
human cancers and tends to form aggregates such as amyloids just like the 
globular prion protein (PrP) (Rangel et al., 2014). This indicates that prion-like 
aggregation of mutant p53 could offer a novel mechanism of oncogenesis and that 
of p53 gain-of-function effects.  
1.2 Transcription Factor p63 
The p63 protein of the p53 family is structurally similar to p53 but with 
different functions. Some of these functions include epithelial tissue development, 
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tissue maintenance, and tumor suppression (Yang et al., 1998). The p63 gene 
codes for six isoforms (Figure 1) TAp63 (α, β, γ) and ΔNp63 (α, β, γ) (Yang and 
McKeon 2000). It is suggested that the full length TAp63 has similar functions to 
p53. Meanwhile, the truncated ΔNp63 which lacks the transactivation (TA) domain, 
acts as an inhibitor to p53, TAp63 and, TAp73 (Yang and McKeon 2000). However, 
the three ΔNp63 isoforms are structurally different and appear to have different 
transactivation abilities due to the presence or the absence of the Sterile Alpha 
Motif (SAM) and the Post-Sam domain at the C-terminal (Ghioni et al., 2005).  Thus, 
it is commonly suggested that TAp63 is a tumor suppressor while the ΔNp63 is an 
oncogene. The p63 gene is responsible for the development and differentiation of 
normal skin, oral mucosa, and other tissues of ectodermal origin (Mills et al., 1999). 
The TAp63 isoform is expressed during the initial stages of epithelial layer 
development, while the ΔNp63 isoform is later expressed in mature skin (epidermis) 
to inhibit the effects of the TAp63 isoforms (Koster and Roop 2004) and (Nguyen et 
al., 2006). Mutations of the p63 gene appear to have many apoptotic, proliferative, 
and senescence-like effects in cancerous tissues (Moll and Slade 2004). Because 
of the six different p63 isoforms, the roles, and effects of p63 on apoptosis are 
complex (Gressner et al., 2005). In many tissues, TAp63 induces apoptosis while 
the dominant ΔNp63 isoforms suppress many apoptotic pathways (Thurfjell et al., 
2004). However, many studies have yielded unclear results concerning the 
functions and specific influences of the different p63 isoforms. The immunoreactivity 
of P63 is nuclear. The immunostaining of p63 has the diagnostic utility to prove 
squamous differentiation in poorly differentiated tumors, and to sort out malignant 
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versus benign proliferations in breast and prostate tumors (Kaufmann et al., 2001). 
p63 also identifies squamous differentiation in poorly differentiated carcinomas from 
various sites, particularly when expressed with cytokeratin 5/6 (CK5/6). p63+ and 
CK5/6+ are used by pathologist for poorly differentiated metastatic carcinomas that 
are likely to show squamous carcinoma primaries (Kaufmann et al., 2001). In 
normal tissues, p63 expression is restricted to epithelial cells of stratified epithelial 
such as skin, esophageal, cervical, tonsillar, and bladder tissues. In keratinocytes 
however, the expressed isoform is the ΔNp63 which presumably maintains 
epithelial cell proliferation at the stratum basale (Kaufmann et al., 2001).  
1.3 Murine Double Minute 2 Protein (MDM2)  
 
The Murine (Mouse) Double Minute 2 (MDM2) protein homolog, known also 
as the E3 ubiquitin-protein ligase MDM2, and is an important negative regulator of 
the tumor protein p53 in humans. MDM2 has two main functions. First, it functions 
as a ligase which recognizes and binds the N-terminal of p53. Second, it inhibits 
p53 transcriptional activation (Wade et al., 2006). MDM2 is an oncoprotein which 
induces ubiquitination, antagonizes p53, and may even carry p53-independent 
functions (Wienken et al., 2016). MDM2 is needed for organ and tissue 
development along with homeostasis. This is because unobstructed p53 activation 
leads to p53-overactivation-dependent cell death known as podoptosis (not 
apoptosis). MDM2 has an important mitogenic effect in wound healing after injury, 
where its inhibition interferes with the re-epithelization process (Ebrahim et al., 
2015). MDM2 is a negative regulator of wild type p53 causing its degradation via 
ubiquitination. However, MDM2 cannot degrade mutant p53 due to the presence of 
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a phosphate group. MDM2 also shows different aggregation affinities when binding 
all three related proteins, both individually and collectively. Differences and 
mutations in the DNA binding domain of p53, p63, p73 play a crucial role in the 
binding affinity of MDM2 (Wienken et al., 2016). MDM2 plays an important role in 
the prognosis of many human cancers such as sarcomas, gliomas, melanomas, 
and carcinomas (Onel and Cordon-Cardo 2004). An autoregulatory feedback loop 
made of p53 and MDM2, strongly regulates p53 intracellular levels. Both p53 
mutations and MDM2 overexpression can interrupt this loop and eventually be used 
as a negative prognostic indicator for cancer development (Javid et al., 2015). Even 
though MDM2 overexpression is common in many cancers, MDM2 can be both a 
positive or a negative indicator in tumors, thus still a controversial tumor 
differentiation biomarker (Onel and Cordon-Cardo 2004). In non-small cell lung 
cancer (NSCLC), the immunohistochemical detection of MDM2 favors MDM2 as a 
prognostic marker without the associated p53 expression (Ko et al., 2000). The 
overexpression in NSCLC gives a good prognosis without gene amplification, yet it 
can be correlated with high levels of MDM2 mRNA. Onel and Cordon-Cardo (2004) 
state that the prognostic value of MDM2 remains limited. This is due to the 
complexity of mechanisms involved in MDM2 overexpression in many tissues as 
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2. Functional Interplay 
2.1. The Functions of the p53 and p63 Isoforms in Cancer 
 
Recent oncology studies have shown that the expression of different p53 
isoforms in different patterns may play a role in the regulation of normal and 
cancerous cells. The p53 genes encodes for 12 isoforms (SeJin and Seong, ,2016). 
These isoforms are expressed in normal cells via alternative translational initiation, 
alternative splicing, and alternative promoters. Research has also shown that the 
presence of mutant p53 aggregates may be linked to tumor pathogenesis because 
of the loss-of function (LoF), gain-of function (GoF), and the dominant-negative 
(DN) (SeJin and Seong, 2016). Many efforts have been made to single out 
correlations between the different expressed p53 isoforms (at the protein and the 
mRNA levels) and various cancers. studies such as Hofstetter et al. (2011) used 
different cell lines to study the p53 isoforms and their expression. These cells range 
from colorectal adenomas, mucinous and serous ovarian cancers, breast cancer, to 
squamous cell carcinomas of the head and neck (SCCHN) just to name a few 
(Boldrup and Bourdon, 2007). Fujita et al., (2009) showed that the ratio of p53β to 
Δ133p53α can be used to predict the progression of a colorectal adenoma to a 
carcinoma. The expression of Δ40p53α was found to improve recurrence-free 
survival rates in mucinous ovarian cancer (Hofstetter et al., 2011). Furthermore, 
SCCHNs showed elevated levels of the p53β isoform (Boldrup and Bourdon, 2007). 
Figure 1, from the meta-analysis by SeJin and Seong (2016), summarizes the 
expression pattern of the p53 isoforms in different cancers. Many studies focused 
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on the central core domain of p53 because it is considered as a hot spot for nearly 
all genetic mutations such as R248Q. This later p53 mutant appears to self-
aggregate more than wild type p53 and can seed further aggregation (Bom et al., 
2012). SeJin and Seong (2016) state that p53 aggregation might be partially due to 
a decrease in the thermodynamic stability in the mutant protein’s conformation. 
Additionally, p53 aggregates can further co-aggregate with wildtype p53 and cause 
cytotoxic effects on cells (Bom et al., 2012). 
 
 
Figure 1: p53 isoform expression and distribution in various cancers (SeJin and 
Seong 2016).  
 p53 is suspected as a “seed” for co-aggregation with other homologs such as 
p63 and p73 (Xu et al., 2011). Other in vivo studies demonstrated the accumulation 
of p53 aggregates using a fibrillar specific antibody (OC) or an amyloid oligomer 
specific antibody (A11) in breast cancer and basal cell carcinoma (BCC) FFPE 
From Cancer to Forensics: The Immunohistochemical Characterization of TP63, TP53, and MDM2 Proteins 
Expression in Skin Basal Cell and Squamous Cell Carcinomas. 
12 
 
tissue biopsies (SeJin and Seong 2016). Figure 2 shows the independent research 
that is geared toward p53 aggregation. Currently, cancer is being considered as an 
aggregation disease (Bom et al., 2012). During malignancy proteins are 
uncontrollably expressed with conformational changes. It has been demonstrated 
that the conformation of the p53 DNA-binding domain (DBD) is unstable (Stindt et 
al., 2014). Mutations such as R175H, R249S, and R273H additionally destabilize 
the DBD in p53. Thus, high percentages of these mutant proteins are unfolded and 
thus inactive (Switch laboratory “Cancer as an aggregation disease,” 2014). These 
mutants are found in about 30% of the documented clinical cases and are named 
“structural” mutants. Furthermore, the gain-of-function (GoF) and the dominant-
negative (DN) activity of these structural mutants increase their aggregation 
tendency (Stindt et al., 2014). Figure 3 Shows a native-PAGE of p53 transfected in 
SaOS-2 cells. Furthermore, the structure of the DNA-binding domain (DBD) of p53, 
p63, and p73 exhibit high homology along with aggregation sequences in the same 
structural protein motif which is highlighted in red (Figure 5). The R110P mutant 
p53 was shown to be co-expressed with p63 in SaOS-2 cells. Figure 6 represents a 
3D confocal microscopy image of a formed large p53 and p63 aggregates in the 
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Figure 2: Independent research on the aggregation of p53. 
 
Figure 4: Native-PAGE: p53 transfected in SaCo-2 cells. (Switch Laboratory. 
Cancer as an aggregation disease, 2014).  
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 Figure 7 shows a schematic diagram of cell responses to DNA damage and 
the hypothesis of p53 aggregation. Under normal conditions, wildtype p53 tetramers 
are formed in response to cellular stress due to DNA damage. p53 then bind to the 
response elements and activate other tumor suppressing proteins such as p21. 
However, when a TP53 gene mutation occurs, it alters the expression of p53. This 
leads to the aggregation of expressed mutant p53, wildtype p53, and different 
isoforms. 
2.2  The Functional Interplay of p53, p63, p73 and MDM2 
During malignancy, Proteins are either uncontrollably over-expressed or 
structurally changed due to mutations causing changes in protein-protein 
interactions and functional activity (Stindt et al., 2014). Sometimes, it is still unclear 
whether the aggregation of tumor suppressors and oncogenes contribute to cancer 
progression and malignancy. 
 
Figure 5: The shared homology of the DBD of p53, p63, and p73. (Switch 
Laboratory, Cancer as an aggregation disease, 2014). 
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Figure 6: p53-p63 aggregation formation in the perinuclear region of a SaOS-2 cell. 
(Switch Laboratory, Cancer as an aggregation disease, 2014). 
 
MDM2 is a key regulator of p53 function and can also bind to mutant p53 via the N-
terminal binding region (Stindt et al., 2014). MDM2 also binds to nuclear p63 and 
facilitates its transport to the cytoplasm for degradation (Galli 2010). Studies by 
(Wang and Fersht, 2015) and (Stindt et al., 2014) showed that there is a possible 
favored binding of MDM2 with mutant and wild type p53 rather than with p63 and 
that MDM2 reliefs the inhibition of p63 activity by binding mutant p53. Figure 6 by 
Gannon (2012) shows the signaling pathway of p53, MDM2, and MDMX. Some 
studies showed that MDM2 inhibits p53 by interacting with the N-terminal 
transactivation (TA) domain. This leads to the suppression of downstream target 
genes associated with tumor suppression (Stindt et al., 2014). On the other hand, 
other studies showed that MDM2 destabilizes p53 via its E3 ligase activity. 
From Cancer to Forensics: The Immunohistochemical Characterization of TP63, TP53, and MDM2 Proteins 
Expression in Skin Basal Cell and Squamous Cell Carcinomas. 
16 
 
Furthermore, p53 can also upregulate the expression of MDM2 by binding the p53 
consensus sequence found on the MDM2 promoter region. Ryan et al (2001) has 
demonstrated that p53 is also able to maintain its own levels of expression via the 
upregulation of MDM2. This later pattern of interactions forms a negative feedback 
mechanism which maintains low levels of p53. p73 is another p53 family member. It 
is also involved in cell cycle regulation and apoptosis. Thus, considered a tumor 
suppressor as well (Harms and Chen, 2006). Unlike p53, MDM2 overexpression 
stabilizes p73 instead. However, many studies have shown inconsistent data on the 
effects of MDM2 on p63 transactivation, stability, and binding affinity (Lustig 2012). 
 
Figure 7: a schematic diagram of cell responses to DNA damage and p53 
aggregation. 
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Figure 8: p53-MDM2-MDMX signaling pathway (Gannon, 2012) 
Little (2001) states that MDM2 is unable to physically interact with either the 
Tap63 or ΔNp63. On the other hand, findings by (Lusting 2012) show that unlike 
p53, MDM2 cannot block the p63 transactivation of p21 which is one of the 
pathways for cell cycle arrest. This shows that many interactions between these 
proteins remain unclear. Figure 9 by (Stindt et al., 2014) shows a representation of 
the binding effects of MDM2 on the inhibitory function of mutant p53 on p63 and 
p73.  
 
Figure 8: Representation of the binding effects of MDM2 on the inhibitory function 
of mutant p53, p63,and p73  (Stindt et al., 2014). 
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CHAPTER 3: IMAGEJ AND QuPath DIGITAL SEMI-
QUANTIFICATION OF THE IMMUNOHICTOCHEMICAL 
EXPRESSION OF TP53, TP63, AND MDM2 IN SKIN BASAL CELL 
AND SQUAMOUS CELL CARCINOMAS. 
1. Abstract: 
 Objective: The objective of this study was to evaluate and characterize the 
pattern of p53, p63, and MDM2 tissue expression in 2 types of skin cancers through 
immunohistochemistry (IHC) via innovative image processing softwares such as 
ImageJ and QuPath. Study Design: Three cases of cutaneous cancers: one basal 
cell carcinoma (BCC) and two squamous cell carcinomas (SCCs) were included in 
this study. The cases were diagnosed and classified by a trained pathologist before 
digital pathology image processing. Multiple regions of interest (ROIs) were 
identified in all three cases and captured at different magnifications. For each case, 
every ROI was  at the exact region of the slide for each protein stained. This was 
repeated for each cancer case. 13 ROIs for each protein in the BCC case (total of 
39 ROIs), 14 ROIs for each protein in the SCC (HIV+) case (total of 42 ROIs), and 9 
ROIs for each protein in the SCC case (a total of 27 ROIs). Materials and 
Methods: Formalin-Fixed Paraffin-Embedded biopsies were obtained from 
Heartland Pathology Consultants Edmond, OK USA. Immunohistochemical staining 
was carried out using monoclonal antibodies for p53, p63, and MDM2. The semi-
quantification of positive stain percentages in each ROI was performed via manual 
thresholding and the IIHC profiler plugin, both features of the ImageJ (FIJI) image 
processing software. The nucleus to cytoplasm ration was determined in all cases 
using the most representative ROIs. This was achieved via QuPath, a software for 
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quantitative pathology. Results and Conclusions: Our results indicate that an 
increase in dysplasia and histological tumorous features such as tumor nests 
correlates with an increase in tissue expression of p63 and MDM2 but not p53.    
p53 was the least expressed protein in all three cases with weaker in intensity when 
present. P53 was strong in intensity in one specific region of the epidermis in the 
SCC. p63 exhibited strong and strict nuclear expression in all cases while MDM2 
had strong immunoreactivity but was expressed both in the nucleus and cytoplasm 
of cells in all three cases. MDM2 also was expressed in the subdermal layer and 
connective tissue. p63 was highly significant in differentiating the three cancer 
cases (p-value = 0.0007) followed by p53 which was marginally significant (p-value 
= 0.086) while MDM2 was of no significance in differentiating the cancer cases (p-
value = 0.718).  
2. Introduction  
 
The ability to have high resolution images and scans of whole tissue slides is 
critical to tumor identification, biomarker expression, and digital analytics. This 
emerging field of tissue image analysis is referred to as digital pathology (Bankhead 
et al., 2017) and (Hamilton et al., 2014). Digital pathology uses computer and 
software platforms to view digital images of tissue slides via whole slide images 
(WSIs) or regions of interest (ROIs) cropped from the WSIs (Williams et al., 2017). 
WSIs are usually obtained from high resolutions microscopes made specifically for 
digital pathology downstream quantification protocols (Pell et al., 2019). Current 
pathology professionals and researchers have a selection of working softwares to 
choose from, such as CellProfiler (Lamprecht et al., 2007), Icy (De Chaumont et al., 
From Cancer to Forensics: The Immunohistochemical Characterization of TP63, TP53, and MDM2 Proteins 
Expression in Skin Basal Cell and Squamous Cell Carcinomas. 
24 
 
2012), and Fiji which is an updated version of ImageJ (Schindelin et al., 2012). 
These softwares allow researchers to share their findings and analysis solutions in 
the form of plugins, scripts, pipelines, and workflows. This enhances the  
reproducibility of high content imaging results and research protocols respectively 
(Bankhead et al., 2017). The field of digital pathology continues to lack a 
standardized peer-accepted open and accessible software platform for image 
analysis (Satyanarayanan et al., 2013). This means, that without access to 
expensive commercial analytical platforms, users will have to resort to ineffective 
methods such as downsampling and cropping of images (Bankhead et al., 2017). 
This eventually allows them to apply general analysis tools to only a subset of 
imagery data. Thus, compromising reproducibility and causing high result variability 
(Tuomien et al., 2010) and (Marée et al., 2016).  
Our project aims to use image analysis on semi-quantitative tissue 
morphological metrics of cancerous skin in key areas, such as the standardization 
of immunohistochemical stain interpretation, the assessment of tumor cellular 
characteristic, and the correlation of findings with that of pathologist’s diagnostic 
findings. Image processing and analysis in digital pathology potentially provide 
better accuracy, more reproducible results, standardization, and the extraction of 
new information from both novel and existing features and software plugins. (Pell et 
al., 2019). A pathologist’s assessment remains the golden standard in diagnostic 
pathology due to the experience of a trained eye. However, digital pathology helps 
complement such assessment and diagnoses, further improve prediction models, 
and perform functions outside manual capability (Pell et al., 2019). Quantification of 
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immunohistochemical tissues, circularity of cells and nuclei, and nucleus to 
cytoplasm ratios are one of the many metrics digital pathology help incorporate into 
clinical practice and trials (Koelzer et al., 2018). These latter methods provide 
quantifiable data about individual cells of interest and tissue components such as 
glands and tumor nests (Pell et al., 2019). QuPath and ImageJ (currently known as 
FIJI) are open source softwares which allow for digital pathology image analysis. 
These softwares are user friendly, allow whole slide images (WSI) analysis 
including regions of interest (ROIs), and offer extendable solutions complementary 
to diagnoses by a pathologist. The image analysis methodology offers tumor 
identification and biomarker expression evaluation tools (Schindelin et al., 2012). It 
also allows the user to perform powerful batch processing, share new functionality 
algorithms, and analyze complex tissue images (Bankhead et al., 2017). Whole 
slide imaging can easily generate large 2D images or z-stacks where each plane 
may contain up to 40 GB of data. Manual scoring by a pathologist can be difficult 
and sometimes is not satisfactory for large-scale biomarkers studies. This is due to 
the need for reliable, accurate, reproducible analyses for tissue biomarkers and 
their selection for clinical trials. Lately, this has led to the development of new image 
processing softwares for whole slide pathology slides (Bankhead et al., 2017).  
The QuPath software has been a user friendly and a great open-source 
software that addresses many said challenges facing image analysis. It is by far the 
first comprehensive open-source software geared toward whole slide image 
analysis and applications. QuPath is characterized by a functional cross-platform 
core that is multithreaded and has a tile-based whole slide viewer. This software 
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also offers new algorithms for powerful scripting functionality. The QuPath 
functionality has algorithms such as tissue microarray (TMA) analysis, whole tissue 
section analysis, cell detection and classification, feature computation, and survival 
analysis (Bankhead et al., 2017). One of the main advantages of QuPath and 
ImageJ is that users can add their own extensions based either on challenges they 
have faced or aims of their projects. Furthermore, one the key feature of this 
software is that it is an “object” based data model (Bankhead et al., 2017). In this 
case the word “object” refers to a region or a structure of interest within the image 
being analyzed. One can subsequently manipulate such object by either using 
annotations (e.g., drawings, symbols) or automated segmentation commands (e.g., 
detection and separation of individual cell or nuclei). These later functions allow a 
researcher to display any possible relationships between multiple image-objects 
using gigapixel images and object classifiers (Bankhead et al., 2017). One of the 
most applied examples of QuPath and ImageJ is the ability to evaluate the 
presence, localization, and the intensity of biomarkers’ expression in IHC slides 
(Bankhead et al., 2017). These biomarkers are classic tools in the field of 
immunohistochemistry and pathology alike. They are typically detected using 
specific antibodies and chromogens (Bankhead et al., 2017).  In addition to 
measuring biomarker expression, stain intensity, and cell morphology, QuPath and 
ImageJ have a built-in “cell segmentation algorithms” which can detect thousands of 
cells within a single whole slide image (WSI). This later classifies different cell types 
creating a comprehensive phenotypic cellular profile of the WSI or ROI (Bankhead 
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et al., 2017). This allows for the semi-quantitative map out the tissue section and 
the discovery of any subtle morphological features not visible by the naked eye.  
p53 Immunohistochemistry in Pathology  
The most common genetic alterations in human tumors are mutation of the 
TP53 tumor suppressing gene (Rangel et al., 2014). The resulting altered protein 
has an extended half-life and is detectable with IHC. One should also note that 
epigenetic changes can cause protein accumulation. The gene product is a nuclear 
protein; hence the stain is nuclear. One must also note that p53 is detected by 
immunohistochemical stains only if a mutation renders it stable. Nonetheless, the 
protein may not be functional. A mutation can also cause a physiological response 
to genetic damage to some pathways such as that of MDM2 controlling p53. Thus, 
the p53 immunostain is not an obligatory marker for a mutated gene (Pernick, N., 
MD. (2012). P53. Retrieved September 25, 2020, from 
http://www.pathologyoutlines.com/topic/stainsp53.html).  
p63 Immunohistochemistry in Pathology  
The p63 protein is consistently expressed in basal and stem cells of the 
stratified epithelium. Six different isoforms exist with unknown functions. Both p63 
and p53 belong the second tier of antibodies required by a standard surgical 
pathology laboratory. Positive staining (normal) for p63 consists of the following 
tissues and tissue organs: 1) Breast’s myoepithelium (Am J Surg Pathol 
2001;25:1054). 2) Gynecologic tract’s basal and parabasal cells of mature cervical, 
vaginal, and vulval squamous epithelium. 3) prostate basal cells. 4) Skin basal cells. 
From Cancer to Forensics: The Immunohistochemical Characterization of TP63, TP53, and MDM2 Proteins 
Expression in Skin Basal Cell and Squamous Cell Carcinomas. 
28 
 
5) thymus epithelial cells. 6) Urothelium. 7) Lungs’ bronchial reserve cells, 
metaplastic squamous bronchial epithelium of the lower strata. Tumor protein 63 
can positively be diagnostic to diseases such squamous cell carcinoma and 
squamous component of adenosquamous carcinoma. The p63 stain is typically 
nuclear (Pernick, N., MD. (2012). P53. Retrieved September 25, 2020, from 
http://www.pathologyoutlines.com/topic/stainsp63.html).  
MDM2 Immunohistochemistry in Pathology  
Overexpressed in atypical lipomatous tumors such as dedifferentiated, and 
well differentiated liposarcomas (along with CDK4). Sarcomas like 
myxofibrosarcoma, leiomyosarcoma, and synovial sarcomas also show an 
MDM2/CDK4 overexpression (Pernick, N., MD, 2013. Retrieved September 25, 
2020, from http://www.pathologyoutlines.com/topic/stainsmdm2.html). The MDM2 
protein preferentially labels the perinuclear membrane in the granular layer of 
verrucous carcinoma tumor cells whereas it shows weak and sometimes strong 
cytoplasmic staining (Ouban et al., 2003). 
Image Fundamentals  
Digital images are made of pixels or picture elements where each pixel is a 
number. When image is displayed, the pixels’ values are converted to squares of 
shades of gray (Bankhead et al., 2017). The goal of image analysis is to make 
sense of the converted values in a meaningful display pattern. Fluorescent images 
are additive and quantitative while brightfield images are subtractive and far less 
quantitative (Bankhead et al., 2017).  
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 An object refers to a pathological feature in the representative section of a 
specimen which is annotated which mean selected or drawn (Bankhead et al., 
2017). This term can refer to a cell, a nucleus, or a selected region also referred to 
as a region of interest (ROI). Drawing regions of interest is one of the most 
frequently used features in digital pathology. ROI uses include the measurement of 
lengths and areas, the identification where of location where an analysis should be 
applied, and the selection of training regions for the classifier feature (Bankhead et 
al., 2017). The following picture (Figure 1) shows the type of annotations possible 
for an ROI selection.  
 
 




Counting cells is an especially important task for image analysis purposes 
and there are different ways to do it (Schindelin et al., 2012). Some methods are 
manual while others are automated. The automated method allows for simultaneous 
specifications about each cell such as diameter, area, pixel intensity, and nucleus to 
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cytoplasm ratio (Bankhead et al., 2017). Both the QuPath and imageJ platforms 
offer instructions to manually click on individual cell and count them (Bankhead et., 
2017).  
Object detection and classification.  
The classification in this study is divided into positive and negative cells in 
reference to the stain in question (p53, p63, or MDM2). While manual counting can 
be very laborious and does not scale up to large number of objects (nuclei or cells). 
Softwares such QuPath and ImageJ have detection capabilities that are fast, 
accurate, and can yield reproducible results (Bankhead et al., 2017). Features such 
as object detection can help identify regions where the tumor is proliferating faster. 
For example, the number of tumor cells staining positive for Ki67, a marker for 
proliferation (Bankhead et al., 2017). Cells will also be classified as either negative 
or positive depending on the score compartment of nucleus. This score indicates 
how much DAB (3,3′-Diaminobenzidine) is in the nucleus (Schindelin et al., 2012). 
In other words, how brown do the nuclei look to the software. DAB is the chromogen 
used in immunohistochemistry. The DAB chromogen is attached to the secondary 
antibody specific to the protein of interest in IHC.  
3. Methods  
 Skin Cancer Cases 
A total of 3 Formalin-Fixed Paraffin-Embedded (FFPE) skin biopsies 
representing one BCC, one SCC, and one more SCC from an HIV positive patient 
were obtained from Heartland Pathology Consultants (HPC), Edmond Oklahoma. 
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The regions of interest (ROIs) make up the total samples For this study. The three 
cases will be graded per accepted and validated pathology diagnosing standards. 
The histology slides will be developed from pathology archival FFPE blocks. 
Hematoxylin and Eosin (H&E) staining will be performed to examine the morpho-
pathology of the skin biopsies. Slides of the same biopsies will be stained for p63, 
p53, and MDM2 protein immunohistochemistry using the standard antibody 
protocols. Immunohistochemistry is a useful diagnostic tool for the differentiation of 
biomarkers’ expression in different tissues. 
 Formalin-Fixed Paraffin-Embedded Tissue Biopsies 
Archival formalin-fixed paraffin embedded (FFPE) tissue biopsies, along with 
their related diagnoses, represent an invaluable source for retrospective studies 
where prognosis and responses to treatment are well documented. The status of 
archival FFPE biopsies is that they serve an important source of material for many 
studies, including cancer proteomics. Nonetheless, proteomic studies face 
challenges such as diseases that progress slowly or malignancies with a larger time 
gap between recurrence and treatment. Furthermore, chemical reactions with 
formaldehyde and the harsh histology processing of the FFPE biopsies remain a 
hurdle for many analyses other than immunohistochemistry. Recent advances have 
been made in proteomic analysis protocols of FFPEs such as liquid-
chromatography and mass spectrometry.  Currently, for pathological diagnosis and 
differentiation, tissues are received from various medical facilities for pathological 
testing and analysis. The tissues are subsequently grossed, sectioned, and 
representative sections or whole biopsies are sent for processing in graded 
From Cancer to Forensics: The Immunohistochemical Characterization of TP63, TP53, and MDM2 Proteins 
Expression in Skin Basal Cell and Squamous Cell Carcinomas. 
32 
 
formalin, alcohol, and xylene. The tissue sections are later embedded in paraffin. 
The frozen tissue blocks are mounted on a microtome, sectioned 5 to 10 μm in 
thickness, and then mounted on charged glass slides for either H/E staining or 
immunohistochemistry.   
Grossing of Specimen  
The skin cancerous biopsies differ in size, body location, patient medical 
history, and preoperative workup, particularly those of the head and neck. The 
grossing starts by describing the biopsies’ shape, color, appearance, and 
measurement. Any abnormal changes located on the superior or inferior surfaces of 
the biopsy such as papules, macules, warts, or lesions should be thoroughly 
described and measured. One proceeds to inking the inferior margin of the 
specimen with any attached soft or adipose tissue, if inking is required for 
cancerous margin determination. Then one starts sectioning the specimen and 
describing the presence of hemorrhagic material, fluids, and the internal 
homogeneity of the specimen. One can either send the whole specimen or 
representative sections given the standard operating procedures. There are two 
general requirements to a skin biopsy grossing technique: representative and 
informative. The representative or adequate technique requires that the sample 
presented should show the most diagnostically valuable parts of the biopsy. The 
informative or definite technique requires the sample presented to have clear and 
unmistakable instructions for embedding and microtomy. When tissue biopsies are 
large, one should cut the biopsy into 3 mm thick sections with an area of 
approximately 20 mm x 30 mm if possible. 
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Tissue Fixation and Processing  
 
Modern biopsy processing includes different auxiliary techniques requiring 
different modes of preservation. Fixation is the most universal technique of 
preservation. As a type of preservation, fixation plays two crucial roles. Besides its 
role of preserving the cellular structures, it also ensures the hardening of the 
specimen. The typical fixative for paraffin embedded tissues is neutral buffered 
formalin (NBF). This is equal to 4% paraformaldehyde in a buffer with added 
methanol to prevent the conversion of formaldehyde to formic acid. For an optimal 
histology protocol, a period of 24 to 48 hours is required for adequate tissue fixation. 
Inadequate fixation can lead to tissue dehydration which eventually results in hard, 
stiff, and breakable specimens while cutting with a microtome. 
Using the tissue processor, the following steps are crucial for preparing tissue for 
embedding and microtomy: 
1. 70% alcohol for 1 hour. 
2. 95% ethanol (95% + 5% methanol).  
3. First absolute ethanol for 1 hour.  
4. Second absolute ethanol for 11/2 hour.  
5. Third absolute ethanol 11/2 hour.  
6. Fourth absolute ethanol for 2 hours.  
7. First clearing agent (Xylene) for 1 hour. 
8. Second first clearing agent (Xylene) for 1 hour.  
9. First wax at 58o C for 1 hour.  
10. Second wax at 58o C for 1 hour.  
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 Paraffin Infiltration, Embedding, and Microtomy 
 
During this step of tissue processing, tissues are dehydrated through graded 
alcohols and xylene to remove the water and allow the infiltration of paraffin into the 
tissue. The tissues are then embedded in paraffin blocks to be cut and stored for 
long periods of time. The most common waxes used are commercial paraffin 
waxes. These waxes normally made of straight carbon chain or n-alkanes between 
20 to 40 carbons. The optimal histological use of the melting points of paraffin 
waxes range from 65o C to 70o C. For routine histology, paraffin melting 
temperature is usually between 56o C to 58o C. Increasing the temperature to 60o to 
65o C range decreases viscosity which allows for better tissue infiltration. While the 
representative sections sent to be embedded are preferably 3mm thick, the slide-
mounted cut sections range from 4 to 6 microns in thickness. 
 Immunohistochemistry  
The IHC staining of all three cases was performed by NEO-Genomics (USA) 
using the proper antibodies for the p53, p63, and MDM2 special IHC staining.  
Image Acquisition  
 Using a combination of CelSens software (Olympus Corporation of the 
Americas, Center Valley, PA, USA) and the IX-71 Olympus inverted fluorescent 
microscope with a DP 72 high-speed camera (Olympus Corporation of the 
Americas, Center Valley, PA, USA), and IHC stained FFPE samples from one BCC 
and two SCC cases. Objectives used include: 4x, 10x, 20x, and 40x. Images were 
acquired individually with the camera and processed via ImageJ and QuPath. 13 
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ROIs were captured from the BCC slides for each of the proteins p53, p63, and 
MDM2 totaling 39 ROIs. 14 ROIs were captured from the SCC (HIV+) slides for 
each of the three proteins totaling 42 ROIs. The ROIs all measured around 4128 x 
2820 pixels.  
Software Download    
The QuPath and ImageJ (FIJI) source code, download, and documentation 
are available at the following webpage respectively: 
https://qupath.readthedocs.io/en/latest/docs/intro/about.html 
https://imagej.net/Fiji 
ImageJ or (FIJI)  is an open-source software which aims to improve and standardize 
the speed, objectivity, and reproducibility of digital pathology image analyses. These 
analyses are geared toward to the interpretation of biomarkers for whole slide 
images and regions of interest. Due to the lack of high-tech instrumentation for 
whole slide imaging, only regions of interests form each slide of each case will be 
considered for this study. QuPath has been developed for research purposes and 
applications by the Centre for Cancer Research & Cell Biology at Queen’s 
University Belfast. This is part of a research project funded by Invest Northern 
Ireland and Cancer and Research UK. On the other hand, the imageJ software 
platform which is a property of the NIH and is also used to analyze the images of 
the histology tissue sections in this study. The research protocol consists of three 
main steps. The first step is the H&E staining of the selected skin pathologies. This 
is a standard step to evaluate the cancer pathological manifestations and to single 
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out areas of cellular interest. The second step is the immunohistochemical staining 
of p63, p53, and MDM2 of the three cancers using the standard antibody protocols. 
Routine diagnosis will be performed by a trained pathologist via visual inspection 
and scoring. The third step is to use a QuPath and ImageJ as tools to compare the 
three cases of skin cancers semi-quantitatively.   
RGB Measurement 
ImageJ analyzes the Red, Green, and Blue (RGB) channels of an image. 
Stain vectors are characterizations of how blue the hematoxylin is and how brown 
the DAB is. This lets the user know if the image is suitable for a semi-quantitative 
downstream analysis using ImageJ itself.  
Manual Thresholding versus The IHC Profiler Plugin 
 In the field of anatomical pathology, immunohistochemistry (IHC) serves as 
the diagnostic and prognostic tool for the identification of diseases markers in 
tissues samples and biopsies (Varghese et al., 2014). These markers are crucial in 
the classification and grading of tumors and diseased tissues. In today’s world of 
pathology, the intensity of the antibodies used in IHC staining of specific markers is 
manually judged and often times require more than one opinion of a pathologist 
(Varghese et al., 2014). The use of a plugin such as IHC Profiler from ImageJ 
facilitates and streamlines the assessment of antibody staining intensity in tissue 
sections. IHC Profiler ImageJ plug-in requires only very few steps to yield semi-
quantifiable data about stain intensity resulting in the thresholding (segmentation) of 
only the positively stained cells in the image (Varghese et al., 2014). This gives a 
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binary view of the image where the stained tissue is black and white. For an 8-bit 
image the value of zero is assigned to a black pixel and the value of 255 is assigned 
to a very black pixel (Varghese et al., 2014). This means the positive nuclei and 
tissue will be black whereas the rest of the ROI is white where tissue, cell, and 
nuclei are unstained. The IHC Profiler plugin is able to do so by deconvoluting the 
IHC image’s colors to 3-3’Diaminobenzadine (DAB) which is the actual stain for the 
biomarker in question and the hematoxylin the counter stain.  
Interactive 3-D Surface Plot  
 The interactive 3-D surface Plot plugin from ImageJ is a tool used to provide 
three-dimensional characterization of the tissue samples and shows the 
homogeneity of tissue samples and also show areas of high conductivity (Schindelin 
et al., 2012).  
4. Results 
 
RGB Measurement  
All the ROIs semi-quantified in this study had values of RGB that fell between 
0 to 255 but not equal to neither 0 nor 255. This indicates that all images were 
suitable for all downstream analyses using imageJ including thresholding of the 
DAB stain and hematoxylin counterstain. 
IHC semi-Quantification of p53, p63, and MDM2 in BCC and SCC cases 
Finally, 9 ROIs were captured from the SCC slides for each of the proteins 
totaling 27 ROIs. This allowed us to semi-quantify the immunohistochemical tissue 
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expression of all three proteins in a total of 108 ROIs under different magnification. 
The semi-quantification of the DAB stain was achieved via ImageJ manual 
thresholding for the SCC (HIV+) case whereas the BCC and the SCC were semi-
quantified via the IHC profiler plug-in in ImageJ also. We chose two different 
methods to show the optional methods to achieve such results. Table 1 shows the 
average percentages of IHC DAB stain in every case for all three proteins.  
 
Table 1: Percent stain of p53, p63, MDM2 in all three skin cancers from all ROIs 
processed via ImageJ manual Thresholding and ImageJ IHC Profiler. 
 
The results of the semi quantification of showed that p53 was the least expressed in 
all three cases. p53 was nearly absent in BBC and but was present in both SCC 
cases. MDM2 had the highest average percentage of positive staining and this is 
due to the act that MDM2 was diffusely positive in the nuclei, cells’ cytoplasm, a 
subdermal tissue of in all cases. p63 stained positive in all cases butt higher in the 
basal cell carcinoma case. 
IHC of p53, p63, and MDM2 in Basal Cell Carcinoma 
  
 
Figure 10: ROI# 2 at X100 magnification. Left p53, middle p63, right MDM2.  
 
p53 % Stain p63 % Stain MDM2 % Stain
BCC 0.21 12.93 15.94
SCC (HIV+) 1.53 7.25 19.96
SCC 1.88 5.97 21.94
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Figure 11: ROI # 11 at X40 magnification. Left p53, middle p63, right MDM2. 
 
 
Figure 12: ROI # 13 at X200 magnification. Left p53, middle p63, right 
MDM2.  
  
IHC of p53, p63, and MDM2 in Squamous Cell Carcinoma (HIV+) 
 
Figure 13: ROI #1 at X40 magnification. Left p53, middle p63, right MDM2.  
 
 
Figure 14: ROI #4 at X100 magnification. Left p53, middle p63, right MDM2.  
 
 
Figure 15: ROI #7 at X200 magnification. Left p53, middle p63, right MDM2.  
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IHC of p53, p63, and MDM2 in Squamous Cell Carcinoma  
 
Figure 16: ROI #2 at X100 magnification. Left p53, middle p63, right MDM2.  
 
Figure 17: ROI #4 at X40 magnification. Left p53, middle p63, right MDM2.  
 
Figure 18: ROI #8 at X100 magnification. Left p53, middle p63, right MDM2.  
          Our results indicate that the tissue expression of p53 was weakly present in 
BCC and SCC (HIV+) tumor cells and was nearly absent in cells of the overlying 
healthy or unhealthy epidermis. However, a considerable part of the unhealthy SCC 
epidermis had strong p53 immunoreactivity whereas there was no tissue expression 
of p53 in the underlying dermal layer. Results also showed that p63’s expression 
increased in the in the tumor cells and features of all cases. p63 epidermal 
expression was normal in the healthy epidermis of all cases. This means that p63 
was absent in the outer most layers of the epidermis, the stratum granulosum 
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(granular layer) and the stratum corneum (cornified layer). p63 was nearly absent in 
the normal unaffected stroma of all cases. MDM2 immunoreactivity was decreased 
in BCC compared to SCC and SCC (HIV+). MDM2.
3D Surface Plot and Tissue Homogeneity Assessment  
          Three ROIs were chosen due to the presence of tumorous features that were 
assessed using the 3D-Surface-Plot ImageJ plugin. One ROI represent each of the 
different cases. Both squamous cell carcinoma cases show less tissue 
heterogeneity whereas the basal cell carcinoma case shows higher homogeneity. 
P63 was chose this analysis due to its strong stain intensity allowing for a better 3D 
surface plotting. 
 
Figure 19: BCC ROI #4 at X40 magnification.  
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Figure 20: BCC ROI#4 shows a lesser color variation compared to both SCC and 





Figure 21: SCC p63 ROI #7 at X40 magnification. 
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Figure 22: SCC p63 ROI #7 3D surface plot.  
 
Figure 23: SCC HIV+ p63 ROI #4 at X100 magnification. The image shows the 
formation of possible lesional skin barrier (red arrow).   
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Figure 24: SCC HIV+ p63 ROI #4 shows 3D surface plot shows the most 
heterogeneity.  
 The 3D surface plot analysis shows the histological epidermal differentiation 
between cases. In all 3 cases, healthy regions of the skin are homogenous while in 
the tumorous skin regions are more heterogenous. The blue areas in the 3D surface 
plot diagrams are expressed with greater number of pixels and correspond to higher 
conductivity.  
5. Discussion  
During this study, using ImageJ and QuPath, we were able extract valuable 
semi-quantifiable IHC data of p63, MDM2 and p53, although p53 was hard protein 
to quantify. This is due to the strong and strict nuclear expression of p63, the diffuse 
nuclear and cytoplasmic MDM2 expression. p53 was hard to quantify in both BCC 
and SCC (HIV+) due to its weak immunoreactivity. Again, the methodology along 
with the results herein emphasize the important and complementary role of digital 
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pathology image processing platforms and software have in the field of pathology. 
p53 as a tumor suppressor is pivotal in the pathogenesis of many cutaneous 
cancers (Oh et al., 2020). The relevance of p53 and p53 mutations in the 
tumorigenesis of BCC and SCC is still not completely understood (Ishibashi et al.,  
2003) and (Campbell et al., 1993).  The p63 protein is expressed as to isoforms. 
Research has shown that Tap63 is a tumor suppressing isoform whereas the 
∆Np63 is an oncogenic isoform (Oh et al., 2020). One can speculate from the 
results herein and the finding of new studies whether the increased expression of 
p53, p63 and MDM2 in BCC and SCC is a consequence of the functional interplay 
between MDM2, wildtype p53, mutant p53, Tap63 and ∆Np63. The study by (Oh et 
la., 2020) factors in the formation of pyrimidine dimers and breaks DNA as a cause 
to such increase in tissue expression of these proteins. MDM2 is one of the major 
negative regulators of p53 (Oh et al., 2020). MDM2 does this either via the E3 
ubiquitin ligase which recognizes the N-terminus of the trans-activation domain of 
p53 or via the inhibition of p53’s transcription (Oh et al., 2020). Millon et al., (2001) 
showed a decrease in MDM2’s expression in human head and neck SCC and that 
this decrease in expression was strongly associated with advanced stages of 
tumors and poor prognoses. The study by Oh et al. (2020) showed a  decrease in 
MDM2 expression in BCC cells as opposed to the healthy overlying epidermis. To 
the best of our knowledge, this contradicts some of our finding where MDM2 was 
increased in expression and p53 was nearly absent in BCC. The ImageJ 3D surface 
plot-in shows significant variation in the tissue histology between BCC, SCC, and 
SCC (HIV+). According to Grammenandi et al., (2016), the 3D plot surface analysis 
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via ImageJ shows epidermal differentiation between the three cases. The SCC 
(HIV+) appears to be the most heterogenous which can indicate the formation of 
lipophilic tissue environment due to damaged cellular components.  Grammenandi 
et al., (2016) suggest that the epidermal tissue differences are due to an increase in 
minerals such calcium anions and potassium and a decrease in low molecular 
weight antioxidants.  
Here in we used advanced digital pathology software to extract valuable data 
from the IHC of p53, p63, and MDM2 in in BCC and SCC cancer cases. We found 
that both p53 and p63 can be used in tandem to differentiate between BCC and 
SCC in some cases where diagnosis can be difficult. We also found conflicting 
results from current research about the tissue expression of p53, p63, and MDM2 in 
BCC and SCC cutaneous cancers. We suggest that future research ought to focus 
exclusively on the IHC of p53 and p63 protein isoforms present in BCC and SCC 
skin cancers. This is due to the direct and pivotal roles these isoforms play in 
different skin layers. We also suggest that future projects can look at the presence 
of p53 and p63 amyloid aggregate in skin cancer due to the role they play in the 
gain-of-function (GoF) or the loss-of- functions of these proteins. We encountered 
few limitations in this study such a small sample (only three cases which make our 
findings comprehensive. Also, QuPath was not optimally compatible with the 
images used in this study because QuPath was originally designated for high 
resolution whole slide images (WSIs) which require specific digital pathology 
scanners.  
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CHAPTER 4:  A SOFTWARE ASSISTED PROTEOMIC MOLECULAR 
COMPARISON OF p53, p63, and MDM2. 
 
1. Abstract: In recent years, protein aggregation has been at the center of 
proteomic and cancer research. Aggregation indicates the troubling instability of 
proteins. Identifying the molecular mechanisms dictating protein aggregation is 
crucial to understanding the pathogenesis of many diseases, the development of 
new diagnostic tests and drug therapeutics. Objective: The objective of this 
chapter was to summarize the data generated by three distinct web servers 
which use artificial intelligence and coding programs about the aggregation 
propensities of p53, p63, and MDM2, protein sequences, locations of amino 
acids and their hydrophobic and hydrophilic characteristics. Study Design: We 
have used three different web servers PATSA 2.0. AGGRESCAN, and FELLS to 
compare and contrast aggregation energies of p53, p63, and MDM2 and 
determine the location of hotspots in their protein sequences. Materials and 
Methods: We used the FASTA sequences of p53, p63, and MDM2 retrieved 
from the Protein Data Bank to run our aggregation stimulations. Results and 
Conclusions: Our results showed differences in the possible aggregation prone 
regions between PASTA 2.0 and AGGRESCAN. PASTA 2.0 predicted only one 
possible region of possible aggregation in p53, p63, and MDM2. Meanwhile 
AGGRESCAN predicted multiple hot spots most of which were clustered in the 
DBD of p53 and dispersed throughout multiple domains in p63. PASTA 2.0 also 
predicted that both p63 and MDM2 have 20 amyloids where p53 only has 6. The 
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FELLS webserver showed that p53 had the highest percentage of possible 
aggregation of 27.48% spanning 108 residues. 
2. Introduction  
Proteins misfolding, aggregation, and multiprotein complexes (MPCs) 
formation occur in numerous human degenerative diseases and are referred to as 
protein misfolding diseases (PMDs) (Dill and McCullum, 2012). These diseases are 
characterized by protein oligomers, protein fibrils, and mature fibrils which can occur 
both intra and extracellularly (Chiti and Dobson, 2006). One of the main models that 
explain the occurrence of these aggregates in their respective diseases is the prion 
model. This later model is based on the prion hypothesis which was pioneered by 
Stanley Prusiner in 1980s. Amyloid aggregates are caused directly by protein 
misfolding and recent research links p53 aggregation with the prion hypothesis 
(Walsh et al., 2014). An increasing number of diseases in different organ systems 
are associated with pathological deposition of protein aggregates (Aguzzi and 
O’connor, 2010). Diseases such as Alzheimer’s disease and amyloidosis are the 
quintessence of such diseases (Aguzzi and O’connor, 2012). Nonetheless, with 
advancements in bottom-up proteomic testing, analytics, and artificial intelligence, 
research has shown that protein aggregation also occurs in the cytoplasm and the 
nucleus as opposed to the extracellular matrix only (Walsh et al., 2014). This 
indicates that amyloidosis encompasses many more diseases than previously 
thought of (Aguzzi and O’connor, 2012). Figure (1) by (Santos et al., 2020) 
summarizes how protein aggregation works against the normal physiological 
functions of proteins.  
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Figure 25: The innate competition between normal protein functions and non-
functional aggregation (Santos et al., 2020).  
 
The ability and tendency of protein to self-aggregate and Co-aggregate with 
other proteins or establish cross-amyloid molecular interactions between co-
aggregated proteins, all depend on the stability of the amyloid "cross-beta" structure 
of the protein (Walsh et al., 2014). Herein, we used three distinct web servers 
PATSA 2.0, AGGRESCAN, and FELLS which use computational algorithms and 
bio-coding (using codes and programs for downstream biological analysis) and 
artificial intelligence to give a sequence based proteomic analysis of aggregation 
propensities and aggregation-prone regions (APRs) known as aggregation hot 
spots (Walsh et al., 2014). Amyloids are protein aggregates which fold together to 
form distinct shapes of many copies of the same protein known as fibrils (Walsh et 
al., 2014). Recent studies have shown that mutant p53 forms aggregates are 
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directly associated with gain-of-function (GoF), loss-of-function (LoF) and a 
dominant negative (DN) effect. ∆N63 isoforms do also show similar characteristics 
when exerting a negative dominant effect on all members of the p53 family. Rangel 
et al (2014) have proposed that these phenomena can be explained via a prion-like 
behavior of mutant p53. Figure (26) by Freed-Pastor and Prives (2012) shows the 
most frequent p53 mutations which occur mainly in the DBD of p53.  
Figure 26: p53 spectrum of mutations in human cancers. (A) Missense mutation 
data of p53 in human patients (N=19,262). (B) Six hot spots residues in p53 with 
their corresponding frequency of occurrence. (C) Most common missense mutations 
at hot spots p53 residues (Freed-Pastor and Prives, 2012). 
The primary function of the ancestral p53 protein is to protect cells from DNA 
damage. This role has been conserved for over a billion years (Belyi et al., 2010). In 
the p53 family, p53 is the most divergent protein when compared to p63 and p73 
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which have a far more stable DBD (Belyi et al., 2010). This is due to the fat that p53 
has taken on multiple tumor suppressing functions when protecting cells from DNA 
damage (Rangel et al., 2014). The evolutionary divergence of the p53 family protein 
is seen in their protein sequences. p53 is remarkably shorter (390 amino acids) than 
p63 (680 amino acids) and p73 (Belyi et al., 2010). p63 and p73 have all of the 
domains whereas p53 lacks some domains such as the Sterile Alpha Motif (SAM) 
domain. The p53 DBD only shares about 60% identify with those of p6 and p73 
(Cino et al., 2016). The DNA binding domain (DBD) of p53 is innately unstable and 
is the cite for nearly all of the cancer causing p53 mutations (Cino et al., 2016). This 
is due to p53’s DBD possessing amyloidogenic sequences and amyloid fibrils 
resulting in a loss-of-function (LoF) (Rangel et al., 2014).  
3. Methods 
 Herein, we propose the use of three different protein aggregation webservers 
to characterize the aggregation propensities of p53, p63, and MDM2. The Prediction 
of Amyloid Structure Aggregation server (PASTA 2.0), Aggregation Scanner 
(AGGRESCAN) server, and the Fast Estimator of Latent Local Structure (FELLS) 
server are platforms that use computational algorithms based on existing and 
validated proteomic data in order to yield accurate stimulations about the protein 
aggregation energies along with the location of the probable aggregation hot spots 
in a protein sequence.  
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PASTA 2.0 Aggregation Web Server 
The redesigned Prediction of Amyloid Structure Aggregation 2.0 (PASTA 2.0) 
software represents a versatile web server for the amino where protein propensities 
can be predicted and calculated from a simple genetic sequence input (preferably a 
FATSA file from UniProt or NCBI online protein data bases). The calculated energy 
functions by PASTA 2.0 shows the stability of the cross-beta amino acid pairing 
between different sequence stretches. The PASTA 2.0 server works best with 
FASTA type protein sequences of any database such as the PDB, UniProt, or NCBI 
databases. These protein amino acid sequences can be either copied and pasted 
from sites such as PDB and NCBI into the input window or downloaded from a 
saved file containing the protein sequence as shown in Figure (27). After entering 
the protein amino acid sequence, it is optional for the user to adjust the energy 
settings such as the top pairing energies and the energy threshold. Walsh et al., 
(2014) state that increasing sensitivity (TPR) will have a negative effect on 
specificity (FPR) of the stimulation and vice versa. The settings during this 
aggregation analysis of p53, p63, and MDM2 were kept on their default values. 
AGGRESCAN Aggregation Web Server 
AGGRESCAN is web server for predicting aggregation-prone regions in a 
protein sequence. It also analyzes the effect of mutations on the aggregation 
propensities of proteins and compares data between different sets (Conchillo-Sole 
et al., 2007). AGGRESCAN also uses FASTA protein sequences from the PDB, 
UniProt, or NCBI databases. Figure (28) shows the sequence input window of 
AGGRESCAN 
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Figure 27:  Screenshot of the PASTA 2.0 input window for protein sequences.  
FELLS Aggregation Web Server.  
The FELLS web server is geared toward visualizing structural features from 
protein sequences. The FELLS webserver yields aggregation and low complexity 
stimulations, disorder regions, and local residual propensities such regions of both 
hydrophobic and amphipathic clusters (Piovesan et al., 2017). The servers can be 
directly accessed via the following links:  
PASTA 2.0: http://old.protein.bio.unipd.it/pasta2/  
AGGRESCAN: http://bioinf.uab.es/aggrescan/  
FELLS: http://old.protein.bio.unipd.it/fells/help 
All of the protein sequences use in our study are in FASTA format and were 
retrieved from the UniProt database. 
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Figure 28: AGGRESCAN protein sequence input window. 
 
Figure 29: The FELLS protein sequence input window.  
4. Results  
We used the PASTA 2.0, AGGRESCAN, and FELLS web servers to extract 
different data which helped characterize the aggregation propensities, the presence 
of beta-sheets, and the possible location of aggregation prone areas (APRs) also 
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known as hot spots. AGGRESCAN showed that nearly all of the DBD domains of all 
9 main p53 isoforms contained aggregation hot spots as shown in Figure (30 to 
38). Surprisingly, none of the most occurring mutations such as R175H, R248Q, 
and R273H which occur in the p53 DBD do not fall within these aggregation prone 
regions. Furthermore, AGGRSCAN shows that many of these aggregation hot spots 
are clustered next to each other in the DBD of p53. The presence of Proline 
residues causes a break in the sequence of aggregation prone regions.  
 
Figure 30: p53 isoform #1 normalized hot spot areas (red squared peaks) and DNA 
binding domain region (green square).  
 
Figure 31: p53 isoform #2 normalized hot spot areas (red squared peaks) and DBD 
region (green box).  
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Figure 32: p53 isoform #3 normalized hot spot areas (red squared peaks) and DBD 
region (green box).    
 
Figure 33: p53 isoform #4 normalized hot spot areas (red squared peaks) and DBD 
region (green box).  
 
Figure 34: p53 isoform #5 normalized hot spot areas (red squared peaks) and DBD 
region (green box).  
 
Figure 35: p53 isoform #6 normalized hot spot areas (red squared peaks) and DBD 
region (green box).  
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Figure 36: P53 isoform #7 normalized hot pot areas (red squared peaks) and DBD 
regions (green box).  
 
Figure 37: P53 isoform #8 normalized hot spot area (red squared peaks) and DBD 
region (green box) 
 
Figure 38: p53 isoform #9 normalized hot spot area (red squared peaks) and DBD 
region (green box).  
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Figures (39) to (50) show the AGGRESCAN aggregation prone regions of p63. The 
p63 protein also a significant number of aggregation hot spots in the DBD regions 
but unlike p53 the hot stops appear less clustered. For both p53 and p63, the 
isoforms do not have the same sequence length which is due to the alternative 
splicing of the p53 and p63 genes. The presence of hot spots in shorter isoform 
makes the protein less stable as the probability of the APRs of being exposed 
increases. When the protein conforms to its quaternary structure some of the hot 
spots end up hidden within the protein and thus have less chance of interacting with 
DNA or other protein regions.  
 
Figure 39: p63 isoform #1 normalized hot spot areas (red squared peaks) DBD 
(green box). 
 
Figure 40: p63 isoform #2 normalized hot spot areas (red squared peaks), DBD 
(green box).  
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Figure 41: p63 isoform #3 normalized hot spot areas (red squared peaks), DBD 
(green box).  
 
Figure 42: p63 isoform #4 normalized hot spot areas (red squared peaks), DBD 
(green box). 
 
Figure 43: p63 isoform #5 normalized hot spot areas (red squared peaks), DBD 
(green box).  
 
Figure 44: p63 isoform #6 normalized hot spot areas (red squared peaks), DBD 
(green box).  
From Cancer to Forensics: The Immunohistochemical Characterization of TP63, TP53, and MDM2 Proteins 




Figure 45: p63 isoform #7 normalized hot spot areas (red squared peaks), DBD 
(green box).  
 
Figure 46: p63 isoform #8 normalized hot spot areas (red squared peaks), DBD 
(green box).  
 
Figure 47: p63 isoform #9 normalized hot spot areas (red squared peaks), DBD 
(green box).  
 
Figure 48: p63 isoform #10 normalized hot spot areas (red squared peaks), DBD 
(green box).  
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Figure 49: p63 isoform #11 normalized hot spot areas (red squared peaks), DBD 
(green box).  
 
Figure 50: p63 isoform #12 normalized hot spot areas (red squared peaks), DBD 
(green box).  
 
 Results from the FELLS software show that p53 had the highest aggregation 
percentage of 27.5% covering a total of 108 residues, p63 had the second highest 
aggregation percentage of 7.9% covering a total of 54 residues, ad third is MDM2 
with the least amount of aggregation with 3.7% covering only 18 residues Figures 
(51, 52, 53). FELLS also showed less aggregation percentages for shorter isoforms 
for both p53 and p63 which is expected with shorter sequences. Relative to their 
protein sequences, p53 has a higher ratio of beta-sheets to residue of 21.6% while 
p63 has only 12.2%. The increased presence of beta-sheets correlates with the 
increase in aggregation propensity of p53 as beta-sheets play a major role in 
inducing protein self and co-aggregation. This correlation does not hold true to for 
MDM2 as it has 14% of beta-sheets, more than p63, but a lesser aggregation 
propensity Figure (53).    
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 Figure 51: Total FELLS structural and aggregation analysis of p53 isoform #1. 
 
Figure 52: Total FEELs structural and aggregation analysis if p63 isoform #1.  
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Figure 53: Total FELLS structural and aggregation analysis of MDM2 isoform #1.  
 The hydrophobic cluster analysis (HCA) shown in Figure (54) and (55) allow 
the user to delineate the protein amino acid sequence and gain insights about regions 
of interest which are likely to be ordered under specific conditions as well as 
disordered regions solely from the amnio acid sequence of the protein. In other words, 
HCA gives a total picture of the protein’s texture with regard to the foldable sequence 
regions.   
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Figure 54: FELLS output for the secondary structure and disorder for p53. p53 DBD 
has prominent hydrophobic clusters and high number of beta strands.  
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Figure 55: FELLS output for p63 also showing prominent hydrophobic clusters in 
the p63 DBD (labeled as p53 DBD due to high homology), the tetramerization motif, 
and the Sterile Alpha Motif (SAM) domain. 
 
 Self-aggregation results showed MDM2 and p63 have the best energies for 
self-aggregation and this is due partly due to the higher number of possible 
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amyloids(20 amyloids) than that of p53 (six amyloids). Nonetheless, p53 has the 
highest percentage of beta-strands Figure (56). 
 
Figure 56: The PASTA 2.0 web server showed that individually, MDM2 (FASTA ID 
spQ00987) and p63 (FASTA ID spQH3D4) have 20 amyloids each whereas p53 




Figure 57: The PASTA 2.0 co-aggregation predictions compared with the self-
aggregation propensities of p53, p63, and MDM2.  
 
PASTA 2.0 predicted that p53  (FASTA ID spP0437) and MDM2 (FASTA ID 
spQ00987) have the least energy required (-5.3024626 PASTA units) for co-
aggregation whereas p53 and p63 require more energy below aggregation 
threshold to co-aggregate. Figure (58) shows that even when mutations happen the 
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aggregation free energy of p53 remains the same indicating that other factors along 
mutations induce changes in the aggregation energy of p53. 
 
Figure 58: Free Energy graph of six of the some of the most occurring p53 
mutations generated via PASA 2.0 (green horizontal line represent the default 
energy threshold of -5 PASTA where 1 PASTA unit = 0.593 Kcal/mol).  
 
5. Discussion  
The tumor suppressing role of p53 is dependent on the p53’s structure and 
its presence in the nucleus. This allows p53 to bind to DNA sequences 
consequently inducing the activation of other genes sine qua non for DNA stability 
(Levine, 1997) and (Vousden et al., 2002). In Normal cells, the expression of p53 is 
strictly regulated leading to a short half-life of 15 to 30 min (Oren et al., 1981). 
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However, when mutations occur, they prolong the half-life of p53 causing 
cytoplasmic and nuclear inclusions (Slade and Moll 2003). The p53 DBD contains 
more that 95% of the cancer-causing missense mutations (Olivier et al., 2002), and 
this causes p53 to lose its functions via changing the conformation of the DBD 
and/or decreasing the molecular thermodynamic stability of protein regions. Results 
from the PASTA 2.0 and the AGGRESCAN web servers yielded different results 
when predicting the aggregation prone regions. For p53, PASTA 2.0 predicted only 
one parallel aggregation hot spot from residue 251 to residue 257 (ILTIITL). This 
region is highly conserved in p53 (Ghosh et al., 2014). This However, 
AGGRESCAN predicted multiple hot spots for p53, which included the conserved 
region from 251 to 257 (ILTIITL), and most of which were clustered in the DBD. It is 
important to note that mutations rarely occur in the conserved region. One can infer 
that this conserved region serves as hot spot for the aggregation of wild-type p53 to 
gain function. Furthermore, Ghosh et al., (2014) state that 327-332 (YFTLQI) 
residue region, another highly conserved region in p53’s tetramerization domain, 
does not aggregate into an amyloid. Our AGGRESCAN results were consist with 
those of Ghosh et al. (2014) except in the p53 isoform 3 where this region was 
predicted as a hot spot. Both PASTA 2.0 and FELLS showed a more stable p63 and 
MDM2 due to their protein length, presence of multiple interactive domains, and 
highly textured protein region both through the hydrophobic cluster analysis (HCA) 
and the disordered sequence regions which help with stable protein folding. p53 
was shown to be the least stable protein due to its shorter protein length of 393 
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amino acids, the occurrence of most mutations in its DBD, and also the presence of 
beta-strands in areas that induce aggregation and protein instability.  
Currently, cancer is being considered as an aggregation disease (Bom et al., 
2012). During malignancy proteins are uncontrollably expressed with conformational 
changes. It has been demonstrated that the conformation of the p53 DNA-binding 
domain (DBD) is unstable (Stindt et al., 2014). Mutations such as R175H, R249S, 
and R273H additionally destabilize the DBD in p53. Thus, high percentages of 
these mutant proteins are unfolded and thus inactive. These mutants are found in 
about 30% of the documented clinical cases and are named “structural” mutants. 
Furthermore, the gain-of-function (GoF) and the dominant-negative (DN) activity of 
these structural mutants increase their aggregation tendency (Stindt et al., 2014). 
Mutations and aggregation alike cause the structural changes that lead to protein 
instability, the inability to bind DNA and induce gene transactivation, and the loss of 
function such as the suppression of tumors (Ghosh et al., 2014). Our web-server 
based analyses, although not confirmatory, showed different aspects of aggregation 
in p53, p63, and MDM2. Our results showed that there are multiple factors that 
dictate potential aggregation such as mutations, conserved protein sequences, 
length of the protein sequence, and the presence of beta-strands and hydrophobic 
clusters. Our stimulations also show the presence of intrinsic aggregation and 
amyloidogenic sequences in p53. When wild-type p53, some of these aggregation 
prone regions are hindered within the folded proteins. Nonetheless, factors such as 
mutations, stress, and solubility can cause a full-length aggregation of proteins such 
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as p53 leading to the formation of amyloids and amyloid fibrils. This causes the loss 
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CHAPTER 5: THE POTENTIAL USES OF p53 IN THE AGE 
ESTIMATION OF ANTERMORTEM AND POSTMORTEM WOUNDS 
FOR FORENSIC PATHOLOGY APPLICTAIONS. 
 
1. Introduction  
In forensic pathology, wound examination is an indispensable practice. It is of 
great importance to determine the age of a wound and its vitality (Toshikazu 2006). 
This can correctly determine the age of cutaneous trauma such as wounds, bruises, 
and scratches. Wound age determination is a classic practice in forensic pathology 
and remains a challenge to interpret in a forensic-judicial setting (Toshikazu 2006). 
The healing of a skin wound is a well-orchestrated physiological and anatomical 
process (Azza et al.,2019). Wound healing consists of three main stages. First is 
inflammation which last about 48 hours, second is proliferation of cells such 
fibroblast and keratinocytes, and third is maturation of the skin and tissue 
(Toshikazu 2006). Hundreds of biological molecules and substances are involved in 
the process of wound healing (Li et al., 2018). In this summary we focus on the 
potential use of both p53 to estimate the age of skin injuries such as wounds, 
bruises, and scratches in a forensic setting. Due to the direct involvement of this 
protein in skin development and skin cell apoptosis. We proposed a rational that is 
deduced from previous research findings to present p53 as a potential candidate for 
the estimation of cutaneous injuries. We also propose that future proteomic tests 
ought to be developed to complement the existing biomarkers for wound age 
determination. This rational stems from the way the p53 gene is activated due to 
cellular stress and damage, how pr53 is expressed, and also degraded before and 
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after death. p53 is a potential candidates when estimating the age of cutaneous 
injuries. 
2. Summary of Research Findings   
Recent progress in forensic scientific techniques has opened the door for 
many molecules as potential biomarkers for wound age estimation and wound 
vitality (Li et al., 2018). In recent years, methods such as immunohistochemistry and 
bottom-up proteomics have been used in forensic pathology and have also been 
validated by multiple scientific groups (Dettmeyer 2011). Most of the 
immunohistochemistry studies have focused on inflammatory cells and markers 
associated with the extracellular matrix such as TNF-α, fibronectin, and IL-6 
(Dettmeyer 2011). Wound age estimation is a major aspect in forensic science. 
Forensic pathologists use wound appearance, scab formation, and subdermal 
hemorrhage discoloration as indices for wound age estimation (Yagi et al., 2016). 
Conventional staining methodologies such as the Berlin blue stain can only detect 
hemosiderin in subdermal tissues seven days post-infliction (Yagi et al., 2016). 
However, it remains difficult to objectively estimate wound age in the first few 5 days 
post-infliction (Yagi et al., 2016). Nonetheless, many biomarkers exist, and 
immunohistochemistry remains a valuable tool to visualize the presence of such 
biomarkers. Expressed proteins such the Tau protein, interleukins (ILs), and 
clusters of differentiation (CDs) remain some of the most useful biomarkers in 
forensic pathology.  
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The early expression of p53 protein in wounds from thermal wounds from 12 
hours to 12 days has been shown (Nagata et al., 1999). In this study and the study 
by (Taran et al., 2004), the authors investigated whether the expression of p53 can 
indicate if skin burns in human had taken place ante-mortem or post-mortem. They 
used immunohistochemistry to quantify the level of p53 expression in burned skin 
which did  assist in the estimation of an ante-mortem burn injury. The normal half-
life of p53 protein is in the range of five to 40 minutes (Taran et al., 2004). Hence, 
p53 does not accumulate in cells due to its rapid degradation (Taran et a., 2004). 
Nonetheless, the level of p53 can increase once a wound takes place and this is 
due to DNA damage in the affected area. Once p53 is activated, a tetramer of wild-
type p53 is formed which stabilizes p53, and consequently allow it to accumulate in 
cell (SeJin and Seong 2016).  Studies such as the one by Taran et al., (2004) used 
burn wound biopsies from antemortem and postmortem victims and showed that 
results from living victims cannot be generalized on postmortem wounds. In the 
antemortem samples, the study showed that high levels of p53 expression in 
examined epithelia suggest an early wound where peak expression occurred on day 
two. In the postmortem wounds, peak p53 wound expression was observed in day 
77 postmortem. We have shown through the functional interplay between p53 and 
other proteins necessary for programmed cell death, the p53 expression skin 
cancer pathologies as well as normal epithelia, and the self-aggregation and co-
aggregation of p53, that p53 can potentially be an accurate biomarkers for the 
determination of cutaneous injuries. This particularly possible in antemortem 
injuries. Few studies demonstrated a considerable increase in the expression of p53 
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within the first two day while peak positivity was observed during day nine post 
injury in antemortem rats (Figure 59). The decline of p53 positive cells was shown 
in antemortem skin injuries on day 23. We also suspect a lesser expression of p53 
in postmortem as opposed to antemortem skin trauma. 
 
 
Figure 59: IHC images of skin sections from an adult rat 9 days after a burn injury 
showing strong p53 nuclear staining in the epithelium basal layer (a and b), and in 
the hair follicle (c) in the dermis (Taran et al., 2004). 
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Our literature search did not yield any studies that focus on the application of 
p63 IHC to determine wound age and wound vitality. This does not rule out p63 as a 
candidate for future studies. Future research has to focus on the use of the p53 and 
p63 IHC in the estimation of wound age. This can also be combined with other 
diagnostic tests such as nucleic acid isolation and amplification (p53 mRNA) from 
formalin-fixed paraffin-embedded (FFPEs) skin biopsies from both antemortem and 
postmortem human wounds. Other bottom-up proteomic tests such as protein 
aggregation assays and staining methodologies such as the Congo Red which is 
specific for p53 aggregates that are similar in nature to prion amyloid oligomers and 
fibrils can be complimentary to the p53 IHC of injured skin (Ano et al., 2012). The 
possibility of multiple methodologies will also provide the investigator the 
opportunity to validate and reference their findings about timing skin wounds and 
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